Dr. Zamarin on Lenvatinib Plus Pembrolizumab in Endometrial Cancer

Dmitriy Zamarin, MD, PhD
Published: Wednesday, Sep 20, 2017



Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) in endometrial cancer.

This combination has been evaluated in patients with endometrial cancer and renal cell carcinoma, results of which were presented at the 2017 ASCO Annual Meeting and the 2017 EMSO Congress, respectively. Results in both trials demonstrated promising response rates and progression-free survival, Zamarin says.

The rationale for combining these drugs is not completely clear, says Zamarin, but these trials prove how little is known about the potential of drugs not initially developed to target the immune system.
 
SELECTED
LANGUAGE


Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) in endometrial cancer.

This combination has been evaluated in patients with endometrial cancer and renal cell carcinoma, results of which were presented at the 2017 ASCO Annual Meeting and the 2017 EMSO Congress, respectively. Results in both trials demonstrated promising response rates and progression-free survival, Zamarin says.

The rationale for combining these drugs is not completely clear, says Zamarin, but these trials prove how little is known about the potential of drugs not initially developed to target the immune system.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x